These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7727299)

  • 21. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.
    Colozza M; Sidoni A; Mosconi AM; Cavaliere A; Bisagni G; Gori S; De Angelis V; Frassoldati A; Cherubini R; Bian AR; Rodino C; Mazzocchi B; Mihailova Z; Bucciarelli E; Tonato M;
    Clin Breast Cancer; 2005 Aug; 6(3):253-9. PubMed ID: 16137437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
    Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
    PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy for Chinese women with locally advanced breast cancer.
    Chow LW; Day W; Ng KC
    Am Surg; 2001 May; 67(5):412-6. PubMed ID: 11379638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
    Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
    Fountzilas G; Papadimitriou C; Aravantinos G; Nicolaides C; Stathopoulos G; Bafaloukos D; Kalofonos H; Ekonomopoulos T; Skarlos D; Pavlidis N; Dimopoulos AM
    Oncology; 2001; 60(3):214-20. PubMed ID: 11340372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Havsteen H; Brynjolf I; Svahn T; Dombernowsky P; Godtfredsen J; Munck O
    Cancer Chemother Pharmacol; 1989; 23(2):101-4. PubMed ID: 2910506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
    J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Rondini E; Bella MA; Leonardi F; Savoldi L; Vallisneri C; Camisa R; Bruzzi P;
    Ann Oncol; 2005 Sep; 16(9):1469-76. PubMed ID: 15956038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
    Venturini M; Bruzzi P; Del Mastro L; Garrone O; Bertelli G; Guelfi M; Pastorino S; Rosso R; Sertoli MR
    J Clin Oncol; 1996 Mar; 14(3):764-73. PubMed ID: 8622022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
    Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
    Eur J Cancer; 1992; 29A(1):37-43. PubMed ID: 1445744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
    Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
    Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5-fluorouracil in locally advanced breast cancer.
    Erol K; Baltali E; Altundag K; Guler N; Ozisik Y; Onat DA; Sayek I; Cengiz M; Atahan L; Tekuzman G
    Onkologie; 2005 Feb; 28(2):81-5. PubMed ID: 15662111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.